To Develop an Algorithm for Predicting the Unfavorable Course of Sepsis in Children Based on a Comprehensive Assessment of Immunological, Biochemical and Molecular Genetic Markers

Sponsor
The Republican Research and Practical Center for Epidemiology and Microbiology (Other)
Overall Status
Recruiting
CT.gov ID
NCT06142162
Collaborator
Belarusian State Medical University (Other)
124
1
36
3.4

Study Details

Study Description

Brief Summary

Current study evaluates the relationship between cell immunity, biochemical and genetic markers in patients with sepsis in order to develop algorithm for predicting the course and outcome of severe bacterial infections.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: flow cytometry
  • Diagnostic Test: ELISA
  • Diagnostic Test: RFLP

Detailed Description

  • To study the state of the immune system in patients with sepsis: the content of blood monocyte subpopulations (classical, intermediate and non-classical monocytes), HLA-DR expression on monocytes, CD64 expression on neutrophils, spontaneous and stimulated production of reactive oxygen species by blood neutrophils etc.;

  • To study biochemical blood parameters and genetic polymorphism of immune response genes;

  • To evaluate the relationship between genetic features of the patient's immune system, biochemical blood parameters, immune system cells and the severity of the pathological process.

  • To develop an algorithm to prevent the development of sepsis in children.

Study Design

Study Type:
Observational
Anticipated Enrollment :
124 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
To Develop an Algorithm for Predicting the Unfavorable Course of Sepsis in Children Based on a Comprehensive Assessment of Immunological, Biochemical and Molecular Genetic Markers
Actual Study Start Date :
Jul 1, 2021
Anticipated Primary Completion Date :
Dec 1, 2023
Anticipated Study Completion Date :
Jun 30, 2024

Arms and Interventions

Arm Intervention/Treatment
control

healthy children

Diagnostic Test: flow cytometry
Determination of monocytes subpopulations (classical monocytes (CD14++CD16-, intermediate monocytes (CD14++CD16+ and non-classical monocytes (CD14+/-CD16++) in the blood of patients, evaluation of the HLA-DR expression on monocytes, evaluation of CD64 expression on neutrophils

Diagnostic Test: ELISA
estimation of the TNF-α, LPS, IL-2, IL-4, IL-6, IL-8, IL-10 levels in the serum

Diagnostic Test: RFLP
assessment of polymorphism TNF-α, LTA, IL-4, IL-6, IL-8, IL-10, TLR-2, TLR-4 genes with restriction fragment length polymorphism technique

sepsis-1

children with sepsis on the 1 day

Diagnostic Test: flow cytometry
Determination of monocytes subpopulations (classical monocytes (CD14++CD16-, intermediate monocytes (CD14++CD16+ and non-classical monocytes (CD14+/-CD16++) in the blood of patients, evaluation of the HLA-DR expression on monocytes, evaluation of CD64 expression on neutrophils

Diagnostic Test: ELISA
estimation of the TNF-α, LPS, IL-2, IL-4, IL-6, IL-8, IL-10 levels in the serum

Diagnostic Test: RFLP
assessment of polymorphism TNF-α, LTA, IL-4, IL-6, IL-8, IL-10, TLR-2, TLR-4 genes with restriction fragment length polymorphism technique

sepsis-7

children with sepsis on the 7 day

Diagnostic Test: flow cytometry
Determination of monocytes subpopulations (classical monocytes (CD14++CD16-, intermediate monocytes (CD14++CD16+ and non-classical monocytes (CD14+/-CD16++) in the blood of patients, evaluation of the HLA-DR expression on monocytes, evaluation of CD64 expression on neutrophils

Diagnostic Test: ELISA
estimation of the TNF-α, LPS, IL-2, IL-4, IL-6, IL-8, IL-10 levels in the serum

Diagnostic Test: RFLP
assessment of polymorphism TNF-α, LTA, IL-4, IL-6, IL-8, IL-10, TLR-2, TLR-4 genes with restriction fragment length polymorphism technique

severe bacterial infection

children with severe bacterial infection

Diagnostic Test: flow cytometry
Determination of monocytes subpopulations (classical monocytes (CD14++CD16-, intermediate monocytes (CD14++CD16+ and non-classical monocytes (CD14+/-CD16++) in the blood of patients, evaluation of the HLA-DR expression on monocytes, evaluation of CD64 expression on neutrophils

Diagnostic Test: ELISA
estimation of the TNF-α, LPS, IL-2, IL-4, IL-6, IL-8, IL-10 levels in the serum

Diagnostic Test: RFLP
assessment of polymorphism TNF-α, LTA, IL-4, IL-6, IL-8, IL-10, TLR-2, TLR-4 genes with restriction fragment length polymorphism technique

severe viral infection

children with severe viral infection

Diagnostic Test: flow cytometry
Determination of monocytes subpopulations (classical monocytes (CD14++CD16-, intermediate monocytes (CD14++CD16+ and non-classical monocytes (CD14+/-CD16++) in the blood of patients, evaluation of the HLA-DR expression on monocytes, evaluation of CD64 expression on neutrophils

Diagnostic Test: ELISA
estimation of the TNF-α, LPS, IL-2, IL-4, IL-6, IL-8, IL-10 levels in the serum

Diagnostic Test: RFLP
assessment of polymorphism TNF-α, LTA, IL-4, IL-6, IL-8, IL-10, TLR-2, TLR-4 genes with restriction fragment length polymorphism technique

Outcome Measures

Primary Outcome Measures

  1. monocytes [3 years]

    proportion of classical monocytes (CD14++CD16-), intermediate monocytes (CD14++CD16+) and non-classical monocytes (CD14+/-CD16++); HLA-DR level of expression

  2. neutrophils [3 years]

    percentage of CD64+ neutrophils and CD64 level of expression

  3. cytokines levels in the serum [3 years]

    TNF-α, LPS, IL-2, IL-4, IL-6, IL-8, IL-10 levels in the serum

  4. genes polymorphism [3 years]

    TNF-α, LTA, IL-4, IL-6, IL-8, IL-10, TLR-2, TLR-4 genes polymorphism

Eligibility Criteria

Criteria

Ages Eligible for Study:
1 Month to 18 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:

community-acquired pneumonia, severe course (according to IDSA / ATs criteria) and / or sepsis with different localization of the primary focus (SOFA> 2); availability of written informed consent of the patient's legal representatives for the study.

Exclusion Criteria:

acute and chronic heart failure; renal failure; acute and chronic liver failure; acute and chronic leukemia, severe anemia; HIV infection; immunosuppressive therapy; malignant neoplasms

Contacts and Locations

Locations

Site City State Country Postal Code
1 Republican Research and Practical Centre for Epidemiology and Microbiology Minsk Belarus 220114

Sponsors and Collaborators

  • The Republican Research and Practical Center for Epidemiology and Microbiology
  • Belarusian State Medical University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
The Republican Research and Practical Center for Epidemiology and Microbiology
ClinicalTrials.gov Identifier:
NCT06142162
Other Study ID Numbers:
  • 02.18
First Posted:
Nov 21, 2023
Last Update Posted:
Nov 21, 2023
Last Verified:
Jun 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by The Republican Research and Practical Center for Epidemiology and Microbiology
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 21, 2023